IBEX 3519.334,40▲ +1,20%EuroStoxx 506261,23▲ +0,91%S&P 5007482,71▼ -0,28%€/$1,1438▲ +0,14%Brent77,00▼ -1,31%Bitcoin55.049▲ +1,03%

Breaking

Labour suspends ARTE agreement and mandates review of key articlesDigi sets IPO price at €5.6 per share, aiming for €1.662 billion market capitalisationOracle amasses $638 billion in orders but its cash flow turns negativeSEPE Cancels €20,621 Debt for 52-Year-Old Subsidy RecipientMó Global Eyewear achieves HappyIndex AtWork Platinum seal for the third consecutive yearMERGE launches Startup Contest 2026 to boost Web3 startups between Europe and Latin AmericaLabour suspends ARTE agreement and mandates review of key articlesDigi sets IPO price at €5.6 per share, aiming for €1.662 billion market capitalisationOracle amasses $638 billion in orders but its cash flow turns negativeSEPE Cancels €20,621 Debt for 52-Year-Old Subsidy RecipientMó Global Eyewear achieves HappyIndex AtWork Platinum seal for the third consecutive yearMERGE launches Startup Contest 2026 to boost Web3 startups between Europe and Latin America

Outlook Therapeutics

Latest outlook therapeutics news

1 article

Vial of medication on legal documents with a judge's gavel beside it, in a dimly lit boardroom

Companies

Outlook Therapeutics Faces a Decisive July Between the FDA and Capital Dilution

Outlook Therapeutics faces a crucial July: shareholder meeting for capital increase and FDA decision on its flagship drug. Shares rise 144% in 2026.

Beatriz Lorenzo Aguirre · 9 July 2026